Pharmaceuticals company Alembic announced Q1FY27 results Consolidated Financial Highlights: Total Income: The consolidated total income for Q1FY27 stood at Rs 5,471 lakh, representing an increase of 2.57% YoY from Rs 5,334 lakh in Q1FY26 and a decrease of 12.01% QoQ from Rs 6,218 lakh in Q4FY26. Revenue from Operations: Consolidated revenue from operations for Q1FY27 was Rs 4,874 lakh, compared to Rs 4,975 lakh in Q1FY26 (down 2.03% YoY) and Rs 6,004 lakh in Q4FY26 (down 18.82% QoQ). Net Profit: Consolidated net profit after tax and share of associate's profit for Q1FY27 was Rs 6,489 lakh, showing an increase of 5.27% YoY from Rs 6,164 lakh in Q1FY26 and a decline of 3.34% QoQ from Rs 6,713 lakh in Q4FY26. Total Comprehensive Income: The total comprehensive income for Q1FY27 reached Rs 12,860 lakh, marking a significant growth of 94.58% YoY compared to Rs 6,609 lakh in Q1FY26. This is a substantial recovery from a loss of Rs 3,387 lakh in Q4FY26. Standalone Financial Highlights: Total Income: Standalone total income for Q1FY27 was Rs 5,182 lakh, an increase of 0.94% YoY from Rs 5,134 lakh in Q1FY26 and a decrease of 13.83% QoQ from Rs 6,014 lakh in Q4FY26. Revenue from Operations: Standalone revenue from operations for Q1FY27 stood at Rs 4,627 lakh, representing a decline of 3.38% YoY compared to Rs 4,789 lakh in Q1FY26 and a decline of 19.85% QoQ compared to Rs 5,773 lakh in Q4FY26. Net Profit: Standalone net profit after tax for Q1FY27 was Rs 1,468 lakh, a decrease of 14.25% YoY from Rs 1,712 lakh in Q1FY26, but an increase of 54.04% QoQ from Rs 953 lakh in Q4FY26. Total Comprehensive Income: Standalone total comprehensive income for Q1FY27 was Rs 7,774 lakh, reflecting a significant growth of 263.95% YoY from Rs 2,136 lakh in Q1FY26. Business Highlights & Segment Performance: Active Pharmaceutical Ingredients (API) Business: The segment reported a consolidated revenue of Rs 1,171 lakh in Q1FY27, as against Rs 1,295 lakh in Q1FY26 (down 9.58% YoY) and Rs 983 lakh in Q4FY26 (up 19.13% QoQ). The segment result (profit before taxes and interest) was Rs 166 lakh in Q1FY27 compared to Rs 273 lakh in Q1FY26 and a loss of Rs 117 lakh in Q4FY26. Real Estate Business: The segment recorded a consolidated revenue of Rs 3,703 lakh in Q1FY27, showing a marginal increase of 0.63% YoY from Rs 3,680 lakh in Q1FY26 and a decrease of 26.25% QoQ from Rs 5,021 lakh in Q4FY26. The segment result was Rs 1,398 lakh in Q1FY27 compared to Rs 1,594 lakh in Q1FY26 and Rs 2,097 lakh in Q4FY26. Emphasis of Matter (Electricity Duty Liability): The auditors highlighted a pending electricity duty matter where the company made an aggregate provision for the total principal amount of Rs 2,052.13 lakh for disputed matters filed against the State of Gujarat. The company has deposited Rs 35 crore with the Supreme Court on May 26, 2023, and the appeal has been admitted. Associate and Subsidiary Performance: The consolidated results include a share of associate’s profit of Rs 4,919 lakh for Q1FY27 (Alembic Pharmaceuticals Limited). The subsidiary, Alembic City Limited, reflected a total revenue of Rs 1,241.62 lakh for the quarter. Result PDF